The European Medicines Agency has begun reviewing a number of new medicines for potential pan-EU marketing authorization, including three investigational orphan drugs –Nefecon (budesonide), maribavir and copanlisib, from Calliditas Therapeutics, Takeda Pharmaceutical and Bayer respectively.
The three rare disease drugs are among seven new products that the EMA added to its latest monthly list...








